Company intelligence / Profile preview

WBZ

Wuhan, Hubei, China

Ownership: Private
Development stage: Other

Overview

WBZ is an early-stage biotechnology company focused on the development of next-generation metabolic therapies. The company specializes in the discovery of oral small molecule agonists targeting the GLP-1, GIP, and glucagon receptors for the treatment of obesity, type 2 diabetes, and related metabolic disorders. By leveraging its expertise in medicinal chemistry, WBZ aims to provide potent and convenient alternatives to current injectable peptide-based incretin therapies. The company's pipeline is currently in the pre-clinical stage, with a focus on optimizing lead candidates for clinical entry.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on WBZ.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WBZ.

Explore the full profile